Snehal Patel Acquires 1,800 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 1,800 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was bought at an average cost of $13.75 per share, for a total transaction of $24,750.00. Following the completion of the purchase, the chief executive officer now directly owns 5,550,002 shares in the company, valued at approximately $76,312,527.50. This trade represents a 0.03 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Trading Down 3.3 %

Shares of NASDAQ:GLSI opened at $13.35 on Friday. The company has a 50-day moving average price of $13.15 and a 200-day moving average price of $14.13. The company has a market cap of $175.49 million, a price-to-earnings ratio of -16.69 and a beta of 1.66. Greenwich LifeSciences, Inc. has a 12 month low of $8.00 and a 12 month high of $21.44.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers bought a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth approximately $117,000. Barclays PLC lifted its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences in the third quarter valued at $253,000. Bank of New York Mellon Corp purchased a new position in Greenwich LifeSciences during the 2nd quarter valued at $264,000. Finally, State Street Corp raised its holdings in Greenwich LifeSciences by 4.4% in the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.